Veru Inc. (VERU)
NASDAQ: VERU · Real-Time Price · USD
2.252
-0.028 (-1.24%)
May 8, 2026, 1:26 PM EDT - Market open
Veru Inc. Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
20
Market Cap
36.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | - | - | - |
| Sep 30, 2024 | - | - | - |
| Sep 30, 2023 | 16.30M | -23.06M | -58.59% |
| Sep 30, 2022 | 39.35M | -21.91M | -35.76% |
| Sep 30, 2021 | 61.26M | 18.67M | 43.83% |
| Sep 30, 2020 | 42.59M | 10.79M | 33.92% |
| Sep 30, 2019 | 31.80M | 15.94M | 100.47% |
| Sep 30, 2018 | 15.86M | 2.21M | 16.18% |
| Sep 30, 2017 | 13.66M | -8.47M | -38.29% |
| Sep 30, 2016 | 22.13M | -10.48M | -32.14% |
| Sep 30, 2015 | 32.60M | 8.11M | 33.13% |
| Sep 30, 2014 | 24.49M | -6.97M | -22.15% |
| Sep 30, 2013 | 31.46M | -3.58M | -10.21% |
| Sep 30, 2012 | 35.03M | 16.47M | 88.71% |
| Sep 30, 2011 | 18.57M | -3.66M | -16.46% |
| Sep 30, 2010 | 22.22M | -5.32M | -19.32% |
| Sep 30, 2009 | 27.54M | 1.91M | 7.45% |
| Sep 30, 2008 | 25.63M | 6.31M | 32.68% |
| Sep 30, 2007 | 19.32M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Palatin Technologies | 8.96M |
| Apollomics | 8.84M |
| Evaxion | 7.53M |
| CervoMed | 4.01M |
| Aligos Therapeutics | 2.19M |
| Hyperion DeFi | 813.46K |
| Actinium Pharmaceuticals | 90.00K |
VERU News
- 2 days ago - Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th - GlobeNewsWire
- 4 weeks ago - Veru files $200M mixed securities shelf - TheFly
- 4 weeks ago - Veru files to sell 23.8M shares of common stock - TheFly
- 2 months ago - Veru enrolls first patient in Phase 2b PLATEAU trial of enobosarm - TheFly
- 2 months ago - Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss - GlobeNewsWire
- 2 months ago - Veru Inc. Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference - Transcripts
- 3 months ago - Veru Inc. Earnings Call Transcript: Q1 2026 - Transcripts
- 3 months ago - Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th - GlobeNewsWire